Biotica acquires full rights to rapamycin analogue program from Pfizer

NewsGuard 100/100 Score

Biotica Technology Ltd. (Cambridge, UK) today announced that it has regained full rights from Pfizer Inc. (NYSE: PFE) to its rapamycin analogue program, including transfer of data and materials. Biotica's rapamycin analogue program, partnered in 2006 with Wyeth Pharmaceuticals (acquired by Pfizer in October 2009), includes clinical candidates for the treatment of neuro-inflammatory and other diseases.

"Our compounds are supported by a strong data package generated by Pfizer, and show evidence of meaningful differentiation in diseases with significant unmet need," commented Dr. Edward Hodgkin, Chief Executive Officer of Biotica.

Since the original Research and License Agreement in 2006, Pfizer has explored the potential of these compounds in several diseases, and in particular has extensively profiled candidate drugs in multiple sclerosis and systemic lupus erythematosus. Biotica intends to continue development in these indications.

"Pfizer enjoyed a productive collaboration with Biotica," said Dr. Mary Collins, Chief Scientific Officer, Immunology and Autoimmunity Research Unit, Pfizer. "The decision to return this program to Biotica was made as part of Pfizer's portfolio review process. We wish Biotica success as it moves its analogue program forward."

Having consolidated its leading position in polyketide engineering after acquisition of IP from Bristol-Myers Squibb in 2009, Biotica is advancing a strong pipeline of engineered polyketides including its best-in-class anti-viral cyclophilin inhibitors and the rapamycin analogue program.




The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Research explores the health benefits of resistant starch in plant-based diets